Exposure Levels of Mycophenolic Acid Are Associated with Comorbidities in Children with Systemic Lupus Erythematosus.
Qiaofeng Ye,Guangfei Wang,Jinmiao Lu,Yidie Huang,Junqi Zhang,Lin Zhu,Yiqing Zhu,Jianger Lan,Ziwei Li,Yubing Liu,Hong Xu,Zhiping Li
DOI: https://doi.org/10.1177/09612033211034555
IF: 2.858
2021-01-01
Lupus
Abstract:Introduction Little is known about the relationship between exposure levels of mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil (MMF), and comorbidities of systemic lupus erythematosus (SLE) in children. This study aims to explore this association. Methods Longitudinal data from SLE children, who were taking MMF for immunosuppression and under therapeutic drug monitoring (TDM), were retrospectively collected. Area under the concentration-time curve of mycophenolic acid (MPA) over 24 hours (AUC(0-24h)) was estimated with Bayesian methods. Logistic regression and random forest models were used to explore the association between comorbidities and MPA exposure levels. Results This study included 107 children with 358 times of follow-up (median age 169.02 months). The incidence of diabetes, acute kidney injury (AKI), or pneumonia was significantly associated with AUC(0-24h) (odds ratio [OR] 0.991, 95% confidence interval [CI] 0.982-0.999), SLE duration (OR 1.012, 95% CI 1.002-1.022), lymphocyte percentage (OR 0.959, 95% CI 0.925-0.991), plasma albumin levels (OR 0.891, 95% CI 0.843-0.940), use of aspirin (OR 0.292, 95% CI 0.126-0.633) and hydroxychloroquine (OR 0.407, 95% CI 0.184-0.906). The random forest model showed that albumin and AUC(0-24h) were two important predictors. The case group (with the three comorbidities) had a mean AUC(0-24h) of 73.63 mg center dot h/L, while the control group had a mean AUC(0-24h) of 100.39 mg center dot h/L. Conclusions Increased levels of MPA exposure are associated with decreased incidence odds of diabetes, AKI or pneumonia in SLE children. An AUC(0-24h) of 100.39 mg center dot h/L or an AUC(0-12h) of 50.20 mg center dot h/L could be used as the targeted exposure level for clinical practice.